All News
Juge @Juge_P_A @PhilippeDieude et al Excess of rare variants in JAK-STAT genes in RA-ILD vs RA 57% vs 46%;OR=1.37 95%CI[1.12-1.69]. Elucidates pathophysiology but also possible treatment rationale @RheumNow #ACR22 Abstr#1123 https://t.co/TAA0rODSmV https://t.co/2TjSY4CXDL
Richard Conway RichardPAConway ( View Tweet)
#Abs1260 #acr22 @rheumnow #acrbest Clincial&US eval 54 RA &18 PsA pts: Tenderness aasoctd w/radiographic progress in non-swollen jnts in PsA but not in RA. In tender non-swollen jnts in RA pts, baseline erosions& sonographic synovitis had significant impact on radio progression https://t.co/iqWvHiDeq8
Olga Petryna DrPetryna ( View Tweet)
Uggh!
What would you do if your pt gets pregnant while on MTX & loses her baby, are you liable for accidental abortion? Should you advise termination if a pregnant pt’s health is deteriorating? @GreerDonley (#law professor) on theoretical risks #ACR22 @rheumnow https://t.co/L4FBWcKZnE
TheDaoIndex KDAO2011 ( View Tweet)
Doyen et al. FIND-RA study. RA for >1<10 years. RA-ILD 12%, air trapping 58%, rheumatoid nodules 11%. @RheumNow #ACR22 Abstr#1393 https://t.co/Sy1qwZJq5E https://t.co/ww8HgHT32E
Richard Conway RichardPAConway ( View Tweet)
Aim for drug free remission in early RA? After 1 yr remission Pts randomized to stop Rx vs 1/2 dose. More flares if no Rx. For 1/2 dose if 2 yrs remission randomize to stop or stay at 1/2 dose. 2X more flares if d/c Rx. Abst2013 Arctic rewind #ACR22 @rheumnow #ACRBest Relevant ? https://t.co/nfQPExhbYj
Janet Pope Janetbirdope ( View Tweet)
Plenary:
Real-world observational study >1500 pts with IA, 1 year retention infliximab biosimilar CT-P13 to GP1111 switch was high. Retention was higher in originator-experienced (92vs83%) & low disease activity
Nabi H, DANBIO Abs1112 https://t.co/z84AMUS3GK #ACR22 @RheumNow https://t.co/SgGhd33Esl
Dr. Antoni Chan synovialjoints ( View Tweet)
Does MTX dose matter for COVID mRNA vaccine immunogenicity in RA pts?
Single-center (n=126) with one MTX dose WH post-each vaccine
Similar humoral response
Big error bars suggest other factors more important
ABST0913 #ACR22 @RheumNow
(not pretty graphs but data interesting!) https://t.co/FFfTWiNjUY
David Liew drdavidliew ( View Tweet)
Data from CorEvitas RA registry shows persistence for first-line monotherapy with etanercept, adalimumab and JAKis no different at 12 months. 20-25% switching at 12-months. Clearly more to secondary failure than anti-drug antibodies.
@RheumNow #ACR22
https://t.co/FeP0UAykUg https://t.co/ad9w9lI0Hu
Julian Segan JulianSegan ( View Tweet)
Raadsen et al. RA-specific CV risk specifically targets pre-existing atherosclerotic vessels. So if no baseline CVD, traditional risk factors are main driver rather than RA. Risk without prevalent CVD (HR 1.16 95%CI 0.88 –1.53) @RheumNow #ACR22 Abstr#1408 https://t.co/1Y6WeEFmim https://t.co/qG3RMNnbqt
Richard Conway RichardPAConway ( View Tweet)
Johnson et al. Increased risk of heart failure and heart failure mortality in RA. No improvement over time. @RheumNow #ACR22 Abstr#1204 https://t.co/MGEgmORGuL https://t.co/9zDYjZiCh1
Richard Conway RichardPAConway ( View Tweet)
Pala et al. Increasing disease activity by CDAI associated increasing patient-reported cognitive dysfunction in RA. More pronounced in younger patients. @RheumNow #ACR22 Abstr#1397 https://t.co/eRFxe27qgq https://t.co/NUtTaAcrik
Richard Conway RichardPAConway ( View Tweet)
Meng et al. ESR/CRP and steroid associated increased risk of MACE in IA. NSAIDs/COX-2 and MTX associated reduced risk of MACE in IA. @RheumNow #ACR22 Abstr#1207 https://t.co/OvjNZkpWpy https://t.co/9NMIJPcV9G
Richard Conway RichardPAConway ( View Tweet)
Singh @NamrataRheum et al. 27,421 RA patients, 8225 on b/tsDMARD. b/tsDMARDs did not increase risk of lymphoma. IR 1.68/1000PY (95% CI 1.5-1.9) on csDMARD vs IR 1.73/1000PY (95%CI 1.4-2.1) on b/tsDMARD. @RheumNow #ACR22 Abstr#1210 https://t.co/3Uvz3mvsGM https://t.co/6k3Vqb21KF
Richard Conway RichardPAConway ( View Tweet)
FIND-RA study from Belgium attempts to quantify ILD in early RA. Previously wide ranging estimates 5-20%. They found ILD in 13%. Awaiting full data on ILD severity and progression.
@RheumNow ABST1393 #ACR22
https://t.co/ol4iCTkbn9 https://t.co/RLG1ur21dj
Julian Segan JulianSegan ( View Tweet)
Juge @Juge_P_A @PhilippeDieude et al. RA-ILD patients have shorter telomere length than RA without ILD. RA-ILD similar telomere length to IPF. OR 0.54 for RA-ILD. Assoc with FVC%pred also. @RheumNow #ACR22 Abstr#1122 https://t.co/H5A7unpjjB https://t.co/IjvHmupykM
Richard Conway RichardPAConway ( View Tweet)
QD205 - RA Activity During Pregnancy (abstract #0955) #ACR22
28 yoF with active RA during Pregnancy - What are your treatment options?
https://t.co/jj99qjugFG https://t.co/vioX8xZw0D
Links:
Dr. John Cush RheumNow ( View Tweet)
DANBIO registry: 1600+ pts RA, AxSpA, PsA
Infiximab biosimilar to biosimilar switch (CT-P13 -> GP1111)
Maintenance at 1yr:
>80%
> withdrawal in original IFX naive, but higher BL DA
Do second time switchers do better because of past switch experience?
Abs#1112 #ACR22 @RheumNow https://t.co/IgjhGLVESz
Aurelie Najm AurelieRheumo ( View Tweet)
Yes. But this only accounts for 1/3 of risk to develop clinical RA.
We need a better understanding of the other 2/3 so we can propose efficient preventive interventions.
#ACR22 @RheumNow https://t.co/RRzlAISFK3
Aurelie Najm AurelieRheumo ( View Tweet)
Biosimilar to biosimilar effective in treatment of RA/PsA/AxSpA.
Large study looking at infliximab biosimilar switching - resulted in high retention rates and virtually no change in disease activity.
@RheumNow #ACR22 Abs#1112 https://t.co/uNRXLewo4M
Robert B Chao, MD doctorRBC ( View Tweet)
Most important point from the Great Debate on treating pre-RA.
Are we really treating to prevent RA or are we simply delaying RA onset?
I don't think there is enough data to treat pre-clinical RA with our current arsenal of DMARDs.
What would you do?
@RheumNow #ACR22
Robert B Chao, MD doctorRBC ( View Tweet)
